Application Detail
Description of Medical Service
Dinutuximab beta is indicated for the treatment of high-risk neuroblastoma in patients who have previously received induction chemotherapy and achieved at least a partial response. Dinutuximab beta is an antibody directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells. After binding, dinutuximab beta induces cell death through complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity.Description of Medical Condition
Neuroblastoma is an embryonal tumour of the autonomic nervous system and usually occurs in young children. The tumours are found in sympathetic nervous system tissues, typically in the adrenal medulla or paraspinal ganglia and can present as mass lesions in the neck, chest, abdomen, or pelvis.Reason for Application
Health technology assessentMedical Service Type
TherapeuticPrevious Application Number/s
Not ApplicableAssociated Documentation
Application Form
-Consultation Survey
Consultation Survey (PDF 561 KB)Consultation Survey (Word 70 KB)
PICO Confirmation
-Assessment Report
-Public Summary Document
Public Summary Document (PDF 741 KB)Public Summary Document (Word 596 KB)